Literature DB >> 14374597

Poliomyelitis antibodies in two differing socioeconomic groups within the same city.

M WALTON, J L MELNICK.   

Abstract

Entities:  

Keywords:  ANTIGENS AND ANTIBODIES; POLIOMYELITIS/immunology

Mesh：

Substances：

Year:  1955        PMID： 14374597      PMCID： PMC2599639     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN： 0044-0086


× No keyword cloud information.
  10 in total

1.  Comparative neutralizing antibody patterns to Lansing (type 2) poliomyelitis virus in different populations.

Authors:  J R PAUL; J L MELNICK; J T RIORDAN
Journal:  Am J Hyg       Date:  1952-11

2.  Development of neutralizing antibodies against the three types of poliomyelitis virus during an epidemic period; the ratio of inapparent infection to clinical poliomyelitis.

Authors:  J L MELNICK; N LEDINKO
Journal:  Am J Hyg       Date:  1953-09

3.  Complement fixation with the three types of poliomyelitis viruses propagated in tissue culture.

Authors:  A SVEDMYR; J F ENDERS; A HOLLOWAY
Journal:  Am J Hyg       Date:  1953-01

4.  Coxsackie virus antibody and incidence of minor illness during the summer.

Authors:  M WALTON; J L MELNICK
Journal:  Public Health Rep       Date:  1953-12       Impact factor: 2.792

5.  Social serology; antibody levels in a normal young population during an epidemic of poliomyelitis.

Authors:  J L MELNICK; N LEDINKO
Journal:  Am J Hyg       Date:  1951-11

6.  Age incidence and seasonal development of neutralizing antibodies to lansing poliomyelitis virus.

Authors:  T B TURNER; D H HOLLANDER; S BUCKLEY; U P KOKKO; C P WINSOR
Journal:  Am J Hyg       Date:  1950-11

7.  Preliminary report of epidemiological studies on poliomyelitis and streptococcal infections; Lansing neutralizing antibody and antistreptolysin O surveys of California cities, Texas, North Carolina, Mexico, Pacific Islands, and Japan.

Authors:  W M HAMMON; G E SATHER; N HOLLINGER
Journal:  Am J Public Health Nations Health       Date:  1950-03

8.  Development, persistence, and significance of type 2, poliomyelitis complement-fixing antibody in man.

Authors:  J CASALS; P K OLITSKY; A B SABIN
Journal:  J Exp Med       Date:  1952-07       Impact factor: 14.307

9.  Complement-fixing antibodies to type 2 (Lansing) poliomyelitis virus in a normal population of a subtropical area.

Authors:  N GOLDBLUM; J L MELNICK
Journal:  J Exp Med       Date:  1952-08       Impact factor: 14.307

10.  A specific complement-fixation test for infection with poliomyelitis virus.

Authors:  J CASALS; P K OLITSKY; R O ANSLOW
Journal:  J Exp Med       Date:  1951-08       Impact factor: 14.307
  10 in total
  6 in total

1.  A serologic and clinical survey of poliomyelitis in Caracas, Venezuela, and Galveston, Texas, and the response to Salk vaccine.

Authors:  M Z BIERLY; L L CORIELL; H M FELTON; H FERNANDEZ-MORAN; K SCHAEFFER
Journal:  Am J Public Health Nations Health       Date:  1956-11

2.  Properties of an ideal poliomyelitis vaccine.

Authors:  J R PAUL
Journal:  Bull N Y Acad Med       Date:  1956-10

3.  Poliomyelitis antibodies in Manitoba children.

Authors:  D GREWAR; J KAMINSKY; J C WILT
Journal:  Can Med Assoc J       Date:  1957-02-15       Impact factor: 8.262

4.  A continuing study of the acquisition of natural immunity to poliomyelitis in representative Louisiana households.

Authors:  J P FOX; H M GELFAND; D R LEBLANC; D P CONWELL
Journal:  Am J Public Health Nations Health       Date:  1956-03

5.  Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries.

Authors:  D Y Graham; E Adam; G T Reddy; J P Agarwal; R Agarwal; D J Evans; H M Malaty; D G Evans
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

6.  An endemiological study of enteric virus infections: poliomyelitis, coxsackie, and orphan (ECHO) viruses isolated from normal children in two socioeconomic groups.

Authors:  E I HONIG; J L MELNICK; P ISACSON; R PARR; I L MYERS; M WALTON
Journal:  J Exp Med       Date:  1956-02-01       Impact factor: 14.307
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.